Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shGPX3-41
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
01
Overview
shGPX3-41 is a specific short hairpin RNA (shRNA) designed to silence the expression of extracellular glutathione peroxidase GPX3. Research indicates that high expression of GPX3 is associated with poor patient outcomes in ovarian serous adenocarcinomas and protects ovarian cancer cells from oxidative stress. shGPX3-41 is utilized in preclinical studies, including in vivo mouse models, to investigate the necessity of GPX3 for tumor establishment and to identify its downstream pro-tumorigenic functions in ovarian cancer. Knockdown of GPX3 by shGPX3-41 has been shown to abrogate clonogenicity and intraperitoneal tumor development.
02
Targets
GPX3 (Glutathione peroxidase 3)
Beyond the preview
Go deeper on shGPX3-41.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shGPX3-41.